NR vs NMN: What Two 2026 Human Trials Found

The question “NR vs NMN: which raises NAD+ more?” sounds like it should have a simple winner. Two small head-to-head human trials from 2026 suggest the current evidence is less straightforward. Their results differ, and that matters when interpreting supplement claims or comparing products.

In a 65-person trial lasting 14 days, participants took 1,000 mg per day of NR or NMN. Both groups saw whole-blood NAD+ roughly double. A smaller head-to-head study found large individual variation. Taken together, these findings don’t establish that one supplement consistently raises NAD+ more than the other. They point instead to results that may vary by study and individual. The trials are small and short, so the results should be understood within those limits, not as proof of broader health outcomes.

For shoppers comparing NR and NMN, the practical takeaway is to look closely at what a product actually tells you. Is the dose clearly disclosed? Is there information about testing? These details give you something specific to assess, rather than asking a product or a headline to settle a question the research hasn’t resolved. Transparent labeling doesn’t replace clinical evidence, but it can help make comparisons clearer.

If customers ask which option is “better,” it’s reasonable to explain that these two trials reached different conclusions and that the available summary doesn’t identify a clear winner. Encourage careful reading of product information and discussion with a qualified healthcare professional when appropriate. As more research becomes available, the evidence may offer a clearer comparison. For now, start with the study details, not the hype.